Drug Safety

, Volume 10, Issue 3, pp 203–219 | Cite as

Drug-Induced Depression

Incidence, Avoidance and Management
  • Scott B. Patten
  • Edgar J. Love
Review Article Pharmacoepidemiology

Summary

According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R), drug-induced depression may be classified as an Organic Mood Syndrome, Depressed Type. Unfortunately, the DSM-III-R diagnostic criteria are not sufficiently precise for application in research, and studies of drug-induced depression have rarely utilised these criteria.

Research concerned with drug-induced depression is characterised by a number of methodological complications. These include differing definitions of depression, including depression defined as a symptom, a syndrome, or by diagnostic criteria for a specific mental disorder. In addition, patients undergoing pharmacological treatments for medical illnesses are typically exposed to considerable psychosocial stress due to the suffering and disability associated with illness. These psychosocial factors may in themselves precipitate episodes of depression.

Due to these complicating factors, sophisticated study designs are required to confirm an aetiological role for medications as risk factors for depression. Unfortunately, adequate studies have rarely been conducted, and much of the literature consists of case reports and clinical observations. Consequently, clinicians are frequently required to make clinical judgements about the aetiology of patients’ depressive symptoms in the absence of definitive scientific informationabout the role of drugs. Nevertheless, a knowledge of the relevant literature will assist clinicians in making reasoned judgements about the aetiology, prevention and management of these disorders.

Keywords

Depressive Symptom Oral Contraceptive Reserpine Alprazolam Anabolic Steroid 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aarons RD, Molinoff PB. Changes in the density of beta-adrenergic receptors in rat lymphocytes, heart, and lung after chronic treatment with propranolol. Journal of Pharmacology and Exerimental Therapeutics 221: 439–443, 1982Google Scholar
  2. Aarons RD, Nies AS, Gal J, Hegstrand LR, Molinoff PB. Elevation of β-adrenergic receptor density in human lymphocytes after propranolol administration. Journal of Clinical Investigation 65: 949–957, 1980PubMedCrossRefGoogle Scholar
  3. Adams CD. Metoclopramide and depression. Annals of Internal Medicine 103: 960, 1985PubMedGoogle Scholar
  4. Adams PW, Rose DP, Folkard J, Wynn V, Seed M, et al. Effect of pyridoxine hydrochloride (vitamin B6) upon depression associated with oral contraception. Lancet 1: 897–904, 1973CrossRefGoogle Scholar
  5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd edn, Revised. American Psychiatric Association, Washington DC, 1987Google Scholar
  6. American Psychiatric Association Task Force on DSM-IV. American Psychiatric Association, Washington DC, 1993Google Scholar
  7. Anderson J, Aabro E, Gulman N, Hjelmsted A, Pedersen HE. Antidepressive treatment in Parkinson’s disease. A controlled trial of the effects of nortiptyline in patients with Parkinson’s disease treated with 1-dopa. Acta Neurologica Scandinavica 62: 210–219, 1980CrossRefGoogle Scholar
  8. Arthur CK, Ma DDF. Combined interferon-alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia. Acta Haematologica 89(Suppl. 1): 15–21, 1993PubMedCrossRefGoogle Scholar
  9. Avorn J, Everitt DE, Weiss S. Increased antidepressant use in patients prescribed β-Blockers. Journal of the American Medical Association 255: 357–360, 1986PubMedCrossRefGoogle Scholar
  10. Ayd FJ. Drug-induced depression — fact or fallacy. New York State Journal of Medicine 58: 354–356, 1958PubMedGoogle Scholar
  11. Backon J. Prevalence of depression among Israeli alcoholics. Journal of Clinical Psychology 46: 96–101, 1990PubMedCrossRefGoogle Scholar
  12. Bant W. Antihypertensive drugs and depression: a reappraisal. Psychological Medicine 8: 275–283, 1978PubMedCrossRefGoogle Scholar
  13. Barnes GE, Prosen H. Depression in Canadian general practice attenders. Canadian Journal of Psychiatry 29: 2–10, 1984Google Scholar
  14. Bartels D, Glasser M, Wang A, Swanson P. Association between depression and propranolol use in ambulatory patients. Clinical Pharmacy 7: 146–150, 1988PubMedGoogle Scholar
  15. Beers MH, Passman LJ. Antihypertensive medications and depression. Drugs 40: 792–799, 1990PubMedCrossRefGoogle Scholar
  16. Belmaker RH, Bannet LJ, Birmaher B. The effect of electroconvulsive shock at a clinically equivalent schedule on rat cortical β-adrenoreceptors. Journal of Pharmacy and Pharmacology 34: 275, 1982PubMedCrossRefGoogle Scholar
  17. Biegon A, Israeli M. Localization of the effects of electroconvulsive shock on β-adrenoceptors in the rat brain. European Journal of Clinical Pharmacology 123: 329–334, 1986CrossRefGoogle Scholar
  18. Biegon A, Israeli M. Regionally selective increases in β-adrenergic receptor density in the brains of suicide victims. Brain Research 442: 199–203, 1988PubMedCrossRefGoogle Scholar
  19. Billings RF, Stein MB. Depression associated with ranitidine. American Journal of Psychiatry 143: 915–916, 1986PubMedGoogle Scholar
  20. Billings RF, Tang SW, Rakoff VM. Depression associated with cimetidine. Canadian Journal of Psychiatry 26: 260–261, 1981Google Scholar
  21. Binstock G, Foster LG, Mullane JF. Propranolol and the depression component of anxiety neurosis. Current Therapeutic Research 35: 423–432, 1984Google Scholar
  22. Biriell C, McEwen J, Sanz E. Depression associated with diltiazem. British Medical Journal 299: 796, 1989PubMedCrossRefGoogle Scholar
  23. Blacker CVR, Clare AW. Depressive disorder in primary care. British Journal of Psychiatry 150: 737–751, 1987PubMedCrossRefGoogle Scholar
  24. Blazer DG, Petrie WM, Wilson WP. Affective psychosis following renal transplant. Diseases of the Nervous System 37: 663–667, 1976PubMedGoogle Scholar
  25. Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clinical Pharmacology and Therapeutics 13: 694–698, 1972Google Scholar
  26. Bottner RK, Tullio CJ. Metoclopramide and depression. Annals of Internal Medicine 103: 482, 1985PubMedGoogle Scholar
  27. Bright RA, Everitt DE. β-Blockers and depression. Evidence against an association. Journal of the American Medical Association 267: 1783–1787, 1992PubMedCrossRefGoogle Scholar
  28. Brower KJ, Eliopulos GA, Blow FC, Catlin DH, Beresford TP. Evidence for physical and psychological dependence on anabolic steroids in eight weight lifters. American Journal of Psychiatry 147: 510–512, 1990PubMedGoogle Scholar
  29. Brown RT, Borden KA, Spunt AL, Medenis R. Depression following pemoline withdrawal in a hyperactive child. Clinical Pediatrics 24: 174, 1985PubMedCrossRefGoogle Scholar
  30. Buckley WE, Yesalis CE, Friedl KE, Anderson WA, Streit AL, et al. Estimated prevalence of anabolic stroid use among male high school seniors. Journal of the American Medical Association 260: 3441–3445, 1988PubMedCrossRefGoogle Scholar
  31. Buckner JC, Mandell W. Risk factors for depressive symptomatology in a drug using population. American Journal of Public Health 80: 580–585, 1990PubMedCrossRefGoogle Scholar
  32. Bulpitt CJ, Dollery CT. Side effects of hypotensive agents evaluated by a self-administered questionnaire. British Medical Journal 3: 485–490, 1973PubMedCrossRefGoogle Scholar
  33. Cade R, Spooner G, Schiein E, Pickering M, DeQuesada A, et al. Comaparison of azothioprine, prednisone, and heparin alone or combined in treating lupus nephritis. Nephron 10: 37–56, 1973PubMedCrossRefGoogle Scholar
  34. Caillon E, Schmitt L, Moron P. Acute depressive symptoms after mefloquine treatment. American Journal of Psychiatry 149: 712, 1992PubMedGoogle Scholar
  35. Capella D, Laporte JR, Castel JM, Tristan C, Cos A, et al. Parkinsonism, tremor, and depression induced by cinnarizine and flunarizine. British Medical Journal 297: 722–723, 1988PubMedCrossRefGoogle Scholar
  36. Carney RM, Rich MW, te Velde A, Saini J, Clark K, et al. Prevalence of major depressive disorder in patients in patients receiving betablocker therapy versus other medications. American Journal of Medicine 83: 223–226, 1987PubMedCrossRefGoogle Scholar
  37. Celesia GG, Barr AN. Psychosis and other psychiatric manifestations of levodopa therapy. Archives of Neurology 23: 193–200, 1970PubMedCrossRefGoogle Scholar
  38. Centonze V, Magrone D, Vino M, Caporaletti P, Attolini E, et al. Flunarizine in migraine prophylaxis: efficacy and tolerability of 5 mg and 10 mg dose levels. Cephalalgia 10: 17–24, 1990PubMedCrossRefGoogle Scholar
  39. Checkley S. Neuroendocrine mechanism and the precipitation of depression by life events. British Journal of Psychiatry 160(Suppl. 15): 7–17, 1992Google Scholar
  40. Cherington M. Parkinsonism, L-dopa and mental depression. Journal of the American Geriatrics Society 18: 513–516, 1970PubMedGoogle Scholar
  41. Chetwynd SJ, Pearson V. Alcohol problems among women working in the home. Australian and New Zealand Journal of Psychiatry 17: 259–264, 1983PubMedCrossRefGoogle Scholar
  42. Chouza C, Caamano JL, Aljanati R, Scaramelli A, De Medina O, et al. Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine. Lancet 1: 1303–1304, 1986PubMedCrossRefGoogle Scholar
  43. Cordess C, Folstein M, Drachman D. Psychiatric effects of alternate day steroid therapy. British Journal of Psychiatry 138: 504–506, 1981PubMedCrossRefGoogle Scholar
  44. Cremona-Barbaro A. Propranolol and depression. Lancet 1: 185, 1983PubMedCrossRefGoogle Scholar
  45. Crowder MK, Pate JK. A case report of cimetidine-induced depressive syndrome. American Journal of Psychiatry 137: 1451, 1980PubMedGoogle Scholar
  46. Cummings JL. Depression and Parkinson’s Disease: a review. American Journal of Psychiatry 149: 443–454, 1992PubMedGoogle Scholar
  47. D’Alessandro R, Benassi G, Morganti G. Side-effects of flunarizine. Lancet 2: 463, 1986CrossRefGoogle Scholar
  48. Dassylva B. Verapamil may cause depression. Canadian Journal of Psychiatry 38: 299–300, 1993Google Scholar
  49. Deakin JFW, Owen F, Cross AJ, Dashwood MJ. Studies on the possible mechanisms of action of electroconvulsive therapy: effects of repeated electrically induced seizures on rat brain receptors for monoamines and other neurotransmitters. Psychopharmacology 73: 345–349, 1981PubMedCrossRefGoogle Scholar
  50. DeMuth GW, Ackerman SH. Alpha-methyldopa and depression: a clinical study and review of the literature. American Journal of Psychiatry 140: 534–538, 1983PubMedGoogle Scholar
  51. Dubrovsky B. Effects of adrenal cortex hormones on limbic structures: some experimental and clinical correlations related to depression. Journal of Psychiatry and Neuroscience 18: 4–16, 1993PubMedGoogle Scholar
  52. Duch S, Duch C, Pasto L, Ferrer P. Changes in depressive status associated with topical beta-blockers. International Ophthalmology 16: 331–335, 1992PubMedCrossRefGoogle Scholar
  53. Duits N, Bos FM. Depressive symptoms and cholesterol-lowering drugs. Lancet 341: 114, 1993PubMedCrossRefGoogle Scholar
  54. Eccleston D, Cole AJ. Calcium-channel blockade and depressive illness. British Journal of Psychiatry 156: 889–891, 1990PubMedCrossRefGoogle Scholar
  55. Edwards JG, Inman WHW, Pearce GL, Rawson NSB. Prescription-event monitoring of 10895 patients treated with alprazolam. British Journal of Psychiatry 158: 387–392, 1991PubMedCrossRefGoogle Scholar
  56. Engelberg H. Low serum cholesterol and suicide. Lancet 339: 727–729, 1992PubMedCrossRefGoogle Scholar
  57. Farmer P, Unis AS, Hsu G. Pemoline, depressive symptoms, and escape from dexamethasone suppression. Journal of Clinical Psychopharmacology 3: 331–332, 1983PubMedCrossRefGoogle Scholar
  58. Fawcett JA, Kravitz HM. Alprazolam: pharmacokinetics, clinical efficacy, and mechanism of action. Pharmacotherapy 2: 243–254, 1982PubMedGoogle Scholar
  59. Feder R. Metoclopramide and depression. Journal of Clinical Psychiatry 48: 38, 1987PubMedGoogle Scholar
  60. Fleming O, Seager CP. Incidence of depressive symptoms in users of the oral contraceptive. British Journal of Psychiatry 132: 431–440, 1978PubMedCrossRefGoogle Scholar
  61. Fogelman J. Verapamil caused depression, confusion, and impotence. American Journal of Psychiatry 145: 380, 1988PubMedGoogle Scholar
  62. Freis ED. Mental depressions in hypertnesive patients treated for long periods with large doses of reserpine. New England Journal of Medicine 251: 1006–1008, 1954PubMedCrossRefGoogle Scholar
  63. Gangat AE, Simpson MA, Naidoo LR. Medication as a potential cause of depression. South African Medical Journal 70: 224–226, 1986PubMedGoogle Scholar
  64. Gerber JG, Nies AS. Antihypertensive agents and the drug therapy of hypertension. In Gilman et al. (Eds) The pharmacological basis of therapeutics, 8th ed., pp. 784–813, Pergamon Press, New York, 1990Google Scholar
  65. Giannini AJ. Side effects of metronidazole. American Journal of Psychiatry 134: 329–330, 1977PubMedGoogle Scholar
  66. Gifford LM, Aeugle ME, Myerson RM, Tannenbaum PJ. Cimetidine postmarket outpatient surveillance program. Journal of the American Medical Association 243: 1532–1535, 1980PubMedCrossRefGoogle Scholar
  67. Gift AG, Wood RM, Cahill CA. Depression, somatization and steroid use in chronic obstructive pulmonary disease. International Journal of Nursing Studies 26: 281–286, 1989PubMedCrossRefGoogle Scholar
  68. Glaubiger G, Lefkowitz RJ. Elevated beta-adrenergic receptor number after chronic propranolol treatment. Biochemical and Biophysical Research Communications 78: 720–725, 1977PubMedCrossRefGoogle Scholar
  69. Goble AJ. β-Blocker treatment and depression. Archives of Internal Medicine 152: 649, 1992PubMedCrossRefGoogle Scholar
  70. Golden RN, Evans DL. Beta-blocker therapy and clinical depression. American Journal of Medicine 84: 559–560, 1988PubMedCrossRefGoogle Scholar
  71. Goldzieher JW, Moses LE, Averkin E, Scheel C, Taber BZ. Nervousness and depression attributed to oral contraceptives: a double-blind, placebo-controlled study. American Journal of Obstetrics and Gynecology 111: 1013–1020, 1971PubMedGoogle Scholar
  72. Goodwin FK. Psychiatric side effects of levodopa in man. Journal of the American Medical Association 218: 1915–1920, 1971PubMedCrossRefGoogle Scholar
  73. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson’s disease: a quantitative and qualitative analysis. Journal of Neurology, Neurosurgery and Psychiatry 49: 381–389, 1986CrossRefGoogle Scholar
  74. Govoni S, Battaini F, Magnoni MS, Trabucchi M. Non-vascular central nervous system effects of calcium entry blockers. Cephalalgia 5(Suppl. 2): 115–118, 1985PubMedGoogle Scholar
  75. Green AI, Austin CP. Psychopathology of pancreatic cancer. A psychobiologic probe. Psychosomatics 34: 208–221, 1993PubMedCrossRefGoogle Scholar
  76. Griffin SJ, Friedman MJ. Depressive symptoms in propranolol users. Journal of Clinical Psychiatry 47: 453–457, 1986PubMedGoogle Scholar
  77. Grigg JR. Prednisone mood disorder with associated catatonia. Journal of Geriatric Psychiatry and Neurology 2: 41–44, 1989PubMedCrossRefGoogle Scholar
  78. Hall RCW, Joffe JR. Aberrant response to diazepam: a new syndrome. American Journal of Pscyhiatry 129: 738–741, 1972Google Scholar
  79. Hall RCW, Popkin MK, Kirkpatrick B. Tricyclic exacerbation of steroid psychosis. Journal of Nervous and Mental Disease 166: 738–742, 1978PubMedCrossRefGoogle Scholar
  80. Hall RCW, Popkin MK, Stickney SK, Gardner ER. Presentation of the steroid psychosis. Journal of Nervous and Mental Disease 167: 229–236, 1979PubMedCrossRefGoogle Scholar
  81. Hall RCW, Zisook S. Paradoxical reactions to benzodiazepines. British Journal of Clinical Pharmacology 11: 99S–104S, 1981PubMedCrossRefGoogle Scholar
  82. Harding T. Fenfluramine dependence. British Medical Journal 3: 305, 1971PubMedCrossRefGoogle Scholar
  83. Harding T. Depression following fenfluramine withdrawal. British Journal of Psychiatry 121: 338–339, 1972PubMedCrossRefGoogle Scholar
  84. Hazen PG, Carney JF, Walker AE, Stewart JJ. Depression — a side effect of 13-cis-retinoic acid therapy. Journal of the American Academy of Dermatology 9: 278–279, 1983PubMedGoogle Scholar
  85. Heal DJ, Butler SA, Hurst EM, Buckett WR. Antidepressant treatments, including sibutramine hydrochloride and electroconvulsive shock, decrease βl — but not β2 — adrenoceptors in rat cortex. Journal of Neurochemistry 53: 1019–1025, 1989PubMedCrossRefGoogle Scholar
  86. Henderson CA, Highet AS. Depression induced by etretinate. British Medical Journal 298: 964, 1989PubMedCrossRefGoogle Scholar
  87. Hengeveld MW, Ancion FAJM, Rooijmans HGM. Prevalence and recognition of depressive disorders in general medical inpatients. International Journal of Psychiatry in Medicine 17: 341–349, 1987PubMedCrossRefGoogle Scholar
  88. Herzberg BN, Johnson AL, Brown S. Depressive symptoms and oral contraceptives. British Medical Journal 4: 142–145, 1970PubMedCrossRefGoogle Scholar
  89. Hoschl C. Do calcium antagonists have a place in the treatment of mood disorders. Drugs 42: 721–729, 1991PubMedCrossRefGoogle Scholar
  90. Hullett FJ, Potkin SG, Levy AB, Ciasca R. Depression associated with nifedipine-induced calcium channel blockade. American Journal of Psychiatry 145: 1277–1279, 1988PubMedGoogle Scholar
  91. Ikegami A, Ozaki A, Hideaki H, Sukamoto T, Yamashita A, et al. Neurochemical investigation of the effects of a new diphenylpiperazine calcium antagonist, KB-2796, on the central dopaminergic system of rats. Japanese Journal of Pharmacology 58: 399–405, 1992PubMedCrossRefGoogle Scholar
  92. Jefferson JW. Central nervous system toxicity of Cimetidine: a case of depression. American Journal of Psychiatry 136: 346, 1979PubMedGoogle Scholar
  93. Jibiki I, Maeda T, Yamaguchi N. Metoclopramide-induced parkinsonism and depression. Acta Neurologica Napoli 14: 130–133, 1992Google Scholar
  94. Joffe RT, Denicoff KD, Rubinow DR, Tsokos G, Balow JE, et al. Mood effects of alternate-day corticosteroid therapy in patients with systemic lupus erythematosus. General Hospital Psychiatry 10: 56–60, 1988PubMedCrossRefGoogle Scholar
  95. Johnson J, Bailey S. Cimetidine and psychiatric complications. British Journal of Psychiatry 134: 315–316, 1979PubMedCrossRefGoogle Scholar
  96. Kamerow DB. Anxiety and depression in the medical setting: an overview. Psychiatric Clinics of North America 72: 745–751, 1988Google Scholar
  97. Kashkin KB, Kleber HD. Hooked on hormones? An anabolic steroid addiction hypothesis. Journal of the American Medical Association 262: 3166–3170, 1989PubMedCrossRefGoogle Scholar
  98. Katon W. The epidemiology of depression in medical care. International Journal of Psychiatry in Medicine 17: 93–112, 1987PubMedCrossRefGoogle Scholar
  99. Kay CR. The Royal College of General Practitioners’ Oral Contraception Study: some recent observations. Clinics in Obstetrics and Gynaecology 11: 759–786, 1984PubMedGoogle Scholar
  100. Kellar KJ, Cascio CS, Berstrom DA, Butler JA, Iadarola P. Electroconvulsive shock and reserpine: effects on β-adrenergic receptors in rat brain. Journal of Neurochemistry 37: 830–836, 1981PubMedCrossRefGoogle Scholar
  101. Kellar KJ, Bergstrom DA. Electroconvulsive shock: effects on biochemical correlates of neurotransmitter receptors in rat brain. Neuropharmacology 22: 401–406, 1983PubMedCrossRefGoogle Scholar
  102. Kershner P, Wang-Chen R. Psychiatric side effects of steroid therapy. Psychosomatics 30: 135–139, 1989PubMedCrossRefGoogle Scholar
  103. Klysner R. Drug-induced depression. Pharmacology and Toxicology 71(Suppl. 1): 107–112, 1992PubMedGoogle Scholar
  104. Kraus MF, Burch EA. Methylphenidate hydrochloride as an antidepressant: controversy, case studies, and review. Southern Medical Journal 85: 985–991, 1992PubMedCrossRefGoogle Scholar
  105. Kobayashi T, Yamauchi R, Murata S. Effects of Ca2+ antagonists on high-K+ evokes increase in [Ca2+]i in rat cerebral synaptosomes and hippocampal neurons. Japanese Journal of Pharmacology 58: 417–425, 1992PubMedCrossRefGoogle Scholar
  106. Kurtz S, Ashkenazi I, Melamed S. Major depressive episode secondary to antiglaucoma drugs. American Journal of Psychiatry 150: 524–525, 1993PubMedGoogle Scholar
  107. Kutner SJ, Phillips NR, Hoag EJ. Oral contraceptives, personality, and changes in depression. Contraception 4: 327–336, 1971CrossRefGoogle Scholar
  108. Lechleitner M, Hoppichler F, Konwalinka G, Patsch JR, Braunsteiner H. Depressive symptoms in hypercholesterolaemic patients treated with pravastatin. Lancet 340: 910, 1992PubMedCrossRefGoogle Scholar
  109. Leeton J. The relationship of oral contraception to depressive symptoms. Australian and New Zealand Journal of Obstetrics and Gynaecology 13: 115–120, 1973PubMedCrossRefGoogle Scholar
  110. Leeton J, Leinkram C, Stiglitz J. The relationship of oral contraception to depression. Australian and New Zealand Journal of Obstetrics and Gynaecology 11: 237–240, 1971PubMedCrossRefGoogle Scholar
  111. Lemieux G, Davignon A, Genest J. Depressive states during rauwolfia therapy for arterial hypertension. Canadian Medical Association Journal 74: 522–526, 1956PubMedGoogle Scholar
  112. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alpha. American Journal of Gastroenterology 88: 760–761, 1993PubMedGoogle Scholar
  113. Lewis A, Hoghughi M. An evaluation of depression as a side effect of oral contraceptives. British Journal of Psychiatry 115: 697–701, 1969PubMedCrossRefGoogle Scholar
  114. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. Journal of Affective Disorders 5: 319–332, 1983PubMedCrossRefGoogle Scholar
  115. Ling MHM, Perry PJ, Tsuang MT. Side effects of corticosteroid therapy. Archives of General Psychiatry 38: 471–477, 1981PubMedCrossRefGoogle Scholar
  116. Lugaresi A, Montagna P, Gallassi R, Lugaresi E. Extrapyramidal syndrome and depression induced by flunarizine. European Neurology 28: 208–211, 1988PubMedCrossRefGoogle Scholar
  117. Lydiard RB, Laraia MT, Ballenger JC, Howell EF. Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. American Journal of Psychiatry 144: 664–665, 1987PubMedGoogle Scholar
  118. Lyndon RW, Johnson G, NcKeough G. Nifedipine-induced depression. British Journal of Psychiatry 159: 447–448, 1991PubMedCrossRefGoogle Scholar
  119. Malinow KL, Molina R, Gordon B, Seines OA, Provost TT, et al. Neuropsychiatric dysfunction in primary Sjogren’s syndrome. Annals of Internal Medicine 103: 344–349, 1985PubMedGoogle Scholar
  120. Malone DA, Dimeff RJ. The use of fluoxetine in depression associated with anabolic steroid withdrawal: a case series. Journal of Clinical Psychiatry 53: 130–132, 1992PubMedGoogle Scholar
  121. Mann JJ, Stanley M, McBride A, McEwan BS. Increase serotonin2 and β-adrenergic receptor binding in the frontal cortices of suicide victims. Archives of General Psychiatry 43: 954–959, 1986PubMedCrossRefGoogle Scholar
  122. Masand P, Pickett P, Murray GB. Psychostimulant for secondary depression in medical illness. Psychosomatics 32: 203–208, 1991PubMedCrossRefGoogle Scholar
  123. Mayeux R, Stern Y, Rosen J, Leventhal J. Depression, intellectual impairment, and Parkinson’s disease. Neurology 31: 645–650, 1981PubMedCrossRefGoogle Scholar
  124. McDowell F, Lee JE, Swift T, Sweet RD, Ogsbury JS, et al. Treatment of Parkinson’s syndrome with L dihidroxyphenylalanine (levodopa). Annals of Internal Medicine 72: 29–35, 1970PubMedGoogle Scholar
  125. McKinney WT, Kane FJ. Depression with the use of alphamethyldopa. American Journal of Psychiatry 124: 80–81, 1967PubMedGoogle Scholar
  126. Merimsky O, Reider-Groswasser I, Inbar M, Chaitchik S. Interferon-related mental deterioration and behavioural changes in patients with renal cell carcinoma. European Journal of Cancer 26: 596–600, 1990PubMedCrossRefGoogle Scholar
  127. Meyboom RHB, Ferrari MD, Dielman BP. Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine. Lancet 2: 292, 1986PubMedCrossRefGoogle Scholar
  128. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically-administered interferon-alpha. Neurology 41: 672–676, 1991PubMedCrossRefGoogle Scholar
  129. Micheli FE, Pardal MMF, Giannaula R, Gatto M, Parera IC, et al. Movement disorders and depression due to flunarizine and cinnarizine. Movement Disorders 4: 139–146, 1989PubMedCrossRefGoogle Scholar
  130. Mielczarek J. Methyldopa and depression. British Medical Journal 2: 1471: 1962CrossRefGoogle Scholar
  131. Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Archives of Internal Medicine 149: 2486–2492, 1989PubMedCrossRefGoogle Scholar
  132. Milstein HG. Mental depression secondary to flourouracil therapy for actinic keratosis. Archives of Dermatology 116: 1100, 1980PubMedCrossRefGoogle Scholar
  133. Mindham RHS, Marsden CD, Parkes JD. Psychiatric symptoms during L-dopa therapy for Parkinson’s disease and their relationship to physical disability. Psychological Medicine 6: 23–33, 1976PubMedCrossRefGoogle Scholar
  134. Mishra R, Janowski A, Sulser F. Subsensitivity of the norepinephrine receptor-coupled adenylate cyclase system in the brain: effects of nisoxetine versus fluoxetine. European Journal of Pharmacology 60: 379–382, 1979PubMedCrossRefGoogle Scholar
  135. Moffic HS, Paykel ES. Depression in medical in-patients. British Journal of Psychiatry 126: 346–353, 1975PubMedCrossRefGoogle Scholar
  136. Muldoon MF, Manuch SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. British Medical Journal 301: 309–314, 1990PubMedCrossRefGoogle Scholar
  137. Muller JC, Pryor WW, Gibbons JE, Orgain ES. Depression and anxiety occurring during rauwolfia therapy. Journal of the American Medical Association 159: 836–839, 1955PubMedCrossRefGoogle Scholar
  138. Nilsson A, Almgren PE. Psychiatric symptoms during the postpartum period as related to the use of oral contraceptives. British Medical Journal 2: 453–455, 1968PubMedCrossRefGoogle Scholar
  139. Nimgogaonkar VL, Goodwin GM, Davies CL, Green AR. Down-regulation of β-adrenoceptors in rat cortex by repeated administration of desipramine, electroconvulsive shock and clenbuterol requires 5-HT neurons but not 5-HT. Neuropharmacology 24: 279–283, 1985CrossRefGoogle Scholar
  140. Nolan BT. Acute suicidal depression associated with use of timolol. Journal of the American Medical Association 247: 1567, 1982PubMedCrossRefGoogle Scholar
  141. Okada F. Depression after treatment with thiazide diuretics for hypertension. American Journal of Psychiatry 142: 1101–1102, 1985PubMedGoogle Scholar
  142. Orlando RG. Clinical depression associated with betaxolol. American Journal of Ophthalmology 102: 275, 1986PubMedCrossRefGoogle Scholar
  143. Oppenheim G. Propranolol-induced depression: mechanism and management. Australian and New Zealand Journal of Psychiatry 17: 400–402, 1983PubMedGoogle Scholar
  144. Oswald I, Lewis SA, Dunleavy DLF, Brezinova V, Briggs M. Drugs of dependence though not of abuse: fenfluramine and imipramine. British Medical Journal 3: 70–73, 1971PubMedCrossRefGoogle Scholar
  145. Palinkas LA, Wingard DL, Barrett-Connor E. Chronic illness and depressive symptoms in the elderly: a population-based study. Journal of Clinical Epidemiology 43: 1131–1141, 1990PubMedCrossRefGoogle Scholar
  146. Pandey GN, Heinze WJ, Brown BD, Davis JM. Electroconvulsive treatment decreases β-adrenergic receptor density in the rat brain. Nature 280: 234–235, 1979PubMedCrossRefGoogle Scholar
  147. Pardal MF, Pardal JF, Micheli F. Aggravation of Parkinson’s disease by cinnarizine. Journal of Neurology, Neurosurgery and Psychiatry 51: 158–159, 1988CrossRefGoogle Scholar
  148. Parker DA, Parker ES, Harford TC, Farmer GC. Alcohol use and depressive symptoms among employed men and women. American Journal of Public Health 77: 704–707, 1987PubMedCrossRefGoogle Scholar
  149. Patterson JF. Depression associated with enalapril. Southern Medical Journal 82: 402–403, 1989PubMedCrossRefGoogle Scholar
  150. Perry PJ, Yates WR, Anderson KH. Psychiatric symptoms associated with anabolic steroids: a controlled, retrospective study. Annals of Clinical Psychiatry 2: 11–17, 1990CrossRefGoogle Scholar
  151. Petrie WM, Maffucci RJ, Woosley RL. Propranolol and depression. American Journal of Psychiatry 139: 92–94, 1982PubMedGoogle Scholar
  152. Pierce JR. Cimetidine-associated depression and loss of libido in a woman. American Journal of the Medical Sciences 286: 31–34, 1983PubMedCrossRefGoogle Scholar
  153. Pletscher A. The discovery of antidepressants: a winding path. Experientia 47: 4–8, 1991PubMedCrossRefGoogle Scholar
  154. Pollack MH, Rosenbaum JF, Cassem NH. Propranolol and depression revisited: three cases and a review. Journal of Nervous and Mental Disease 173: 118–119, 1985PubMedCrossRefGoogle Scholar
  155. Pope HG, Katz DL. Affective and psychotic symptoms associated with anabolic steroid use. American Journal of Psychiatry 145: 487–490, 1988PubMedGoogle Scholar
  156. Porter JB, Beard K, Walker AM, Lawson DH, Jick H, et al. Intensive hospital monitoring study of intravenous cimetidine. Archives of Internal Medicine 146: 2237–2239, 1986PubMedCrossRefGoogle Scholar
  157. Prisant LM, Spruill WJ, Fincham JE, Wade WE, Carr AA, et al. Depression associated with antihypertensive drugs. Journal of Family Practice 33: 481–485, 1991PubMedGoogle Scholar
  158. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, et al. Psychiatric complications of long-term interferon alfa therapy. Archives of Internal Medicine 147: 1577–1580, 1987PubMedCrossRefGoogle Scholar
  159. Rihmer Z, Revai K, Arato M, Perenyi A. Two cases of mazindol-induced depression. American Journal of Psychiatry 141: 1497–1498, 1984PubMedGoogle Scholar
  160. Robins AH, McFadyen ML, Lucke W, Wright JP. Effect of the H2-receptor antagonist ranitidine on depression and anxiety in duodenal ulcer patients. Postgraduate Medical Journal 60: 353–355, 1984PubMedCrossRefGoogle Scholar
  161. Rosenfeld AA. Depression and psychotic regression following prolonged methylphenidate use and withdrawal: case report. American Journal of Psychiatry 136: 226–228, 1979PubMedGoogle Scholar
  162. Russell JW, Schuckit MA. Anxiety and depression in a patient on nadolol. Lancet 2: 1286–1287, 1982PubMedCrossRefGoogle Scholar
  163. Ryan HF, Merrill B, Scott GE, Krebs R, Thompson BL. Increase in suicidal thoughts and tendencies. Journal of the American Medical Association 203: 135–137, 1968CrossRefGoogle Scholar
  164. Sabet-Sharghi F, Hutzier JC. Prophylaxis of steroid-induced psychiatric syndromes. Psychosomatics 31: 113–114, 1990PubMedCrossRefGoogle Scholar
  165. Sarai K. Desmethylimipramine-induced decrease in β-adrenergic receptor binding in rat cerebral cortex. Biochemical Pharmacology 27: 2179–2181, 1978PubMedCrossRefGoogle Scholar
  166. Scheinman PL, Peck GL, Rubinow DR, DiGiovanna JJ, Abangan DL, et al. Acute depression from isotretinoin. Journal of the American Acadamy of Dermatology 22: 1112–1114, 1990CrossRefGoogle Scholar
  167. Schleifer SJ, Slater WR, Macari-Hinson MM, Coyle DA, Kahn M, et al. Digitalis and β-blocking agents: effects on depression following myocardial infarction. American Heart Journal 121: 1397–1402, 1991PubMedCrossRefGoogle Scholar
  168. Schubert DSP, Foliart RH. Increased depression in multiple sclerosis patients. Psychosomatics 34: 124–130, 1993PubMedCrossRefGoogle Scholar
  169. Schulberg HC, Saul M, McClelland M, Ganguli M, Christy W, et al. Assessing depression in primary medical and psychiatric practices. Archives of General Psychiatry 42: 1164–1170, 1985PubMedCrossRefGoogle Scholar
  170. Sellinger-Barnette MM, Mendels J, Frazer A. The effect of psychoactive drugs on beta-adrenergic receptor binding in rat brain. Neuropharmacology 19: 447–454, 1980PubMedCrossRefGoogle Scholar
  171. Sethy VH, Harris DW. Effect of norepinephrine uptake blocker on β-adrenergic receptors of the rat cerebral cortex. European Journal of Pharmacology 75: 53–56, 1981PubMedCrossRefGoogle Scholar
  172. Severson JA, Pittman RN, Gal J, Molinoff PB, Finch CE. Genetic influence on the regulation of beta-adrenergic receptors in mice. Journal of Pharmacology and Experimental Therapeutics 236: 24–29, 1986PubMedGoogle Scholar
  173. Sharfstein SS, Sack DS, Fauci A. Relationship between alternate-day corticosteroid therapy and behavioral abnormalities. Journal of the American Medical Association 248: 2987–2989, 1982PubMedCrossRefGoogle Scholar
  174. Shearer RM, Bownes IT, Curran P. Tardive akathisia and agitated depression during metoclopramide therapy. Acta Psychiatrica Scandinavica 70: 428–431, 1984PubMedCrossRefGoogle Scholar
  175. Siegal FP. Lithium for steroid-induced psychosis. New England Journal of Medicine 299: 155–156, 1978PubMedCrossRefGoogle Scholar
  176. Smith BD, Salzman C. Do benzodiazepines cause depression? Hospital and Community Psychiatry 42: 1101–1102, 1991PubMedGoogle Scholar
  177. Snaith RP, McCoubrie M. Antihypertensive drugs and depression. Psychological Medicine 4: 393–398, 1974PubMedCrossRefGoogle Scholar
  178. Sommer BR, Petrides G. A case of baclofen-induced psychotic depression. Journal of Clinical Psychiatry 53: 211–212, 1992PubMedGoogle Scholar
  179. Sorensen PS, Larsen BH, Rasmussen MJ, Kinge E, Iversen H, et al. Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache 31: 650–657, 1991PubMedCrossRefGoogle Scholar
  180. Sorgi P, Ratey J, Knoedler D, Arnold W, Cole L. Depression during treatment with beta-blockers: results from a double-blind placebo-controlled study. Journal of Neuropsychiatry and Clinical Neuroscience 4: 187–189, 1992Google Scholar
  181. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson’s disease. Journal of Nervous and Mental Disease 178: 27–31, 1990PubMedCrossRefGoogle Scholar
  182. Steel JM, Briggs M. Withdrawal depression in obese patients after fenfluramine treatment. British Medical Journal 3: 26–27, 1972PubMedCrossRefGoogle Scholar
  183. Takada M, Kono T, Kitai ST. Flunarizine induces a transient loss of tyrosine hydroxylase immunoreactivity in nigrostriatal neurons. Brain Research 590: 311–315, 1992PubMedCrossRefGoogle Scholar
  184. Tamminga C, Smith RC, Chang S, Haraszti JS, Davis JM. Depression associated with oral choline. Lancet 2: 905, 1976PubMedCrossRefGoogle Scholar
  185. Tang SW, Remington G, Persad E, Rosenblat R. Coadministration of a beta-adrenergic antagonist and a tricyclic antidepressant: a pilot study. Psychiatry Research 33: 101–106, 1990PubMedCrossRefGoogle Scholar
  186. Tennant F, Black DL, Voy RO. Anabolic steroid dependence with opioid-type features. New England Journal of Medicine 319: 578, 1988PubMedCrossRefGoogle Scholar
  187. Theissen BQ, Wallace SM, Blackburn JL, Wilson TW, Bergman U. Increased prescribing of antidepressants subsequent to β-Blocker therapy. Archives of Internal Medicine 150: 2286–2290, 1990CrossRefGoogle Scholar
  188. Thomas MA, Ibanez HE. Interferon alfa-2a in the treatment of subfoveal choroidal neovascularization. American Journal of Ophthalmology 115: 563–568, 1993PubMedGoogle Scholar
  189. Tiller JWG, Schweitzer I. Benzodiazepines: depressants or antidepressants? Drugs 44: 165–169, 1992PubMedCrossRefGoogle Scholar
  190. Todd PA, Benfield P. Flunarizine. A reappraisal of its pharmacological properties and therapeutic use in neurological disorders. Drugs 38: 481–499, 1989PubMedCrossRefGoogle Scholar
  191. Twerski B. Sympathomimetic-induced depression. American Journal of Psychiatry 144: 252, 1987PubMedGoogle Scholar
  192. Voth AJ. Possible association between metronidazole and agitated depression. Canadian Medical Association Journal 100: 1012–1013, 1969PubMedGoogle Scholar
  193. Wagshul AM, Daroff RB. Depression during L-dopa treatment. Lancet 2: 592, 1969PubMedCrossRefGoogle Scholar
  194. Wamboldt FS, Jefferson JW, Wamboldt MZ. Digitalis intoxication misdiagnosed as depression by primary care physicians. American Journal of Psychiatry 143: 219–221, 1986PubMedGoogle Scholar
  195. Warner MD, Peabody CA, Whiteford HA, Hollister LE. Alprazolam as an antidepressant. Journal of Clinical Psychiatry 49: 148–150, 1988PubMedGoogle Scholar
  196. Weddington WW, Banner A. Organic affective syndrome associated with metoclopramide: case report. Journal of Clinical Psychiatry 47: 208–209, 1986PubMedGoogle Scholar
  197. Weddington WW, Muelling AE, Moosa HH. Adverse neuropsychiatric reactions to cimetidine. Psychosomatics 23: 49–53, 1982PubMedGoogle Scholar
  198. Wekking EM. Psychiatric symptoms in systemic lupus erythematosus: an update. Psychosomatic Medicine 55: 219–228, 1993PubMedGoogle Scholar
  199. Wells KB, Hays RD, Burnam MA, Rogers W, Greenfield S, et al. Detection of depressive disorder for patients receiving prepaid or fee-for-service care. Results from the medical outcomes study. Journal of the American Medical Association 262: 3298–3302, 1989PubMedCrossRefGoogle Scholar
  200. Whitlock FA, Evans LEJ. Drugs and depression. Drugs 15: 53–71, 1978PubMedCrossRefGoogle Scholar
  201. Widmer RB. Reserpine: the maligned antihypertensive drug. Journal of Family Practice 20: 81–83, 1985PubMedGoogle Scholar
  202. Wilson JD. Androgens. In Gilman et al. (Eds) The pharmacological basis of therapeutics, 8th ed., pp. 1413–1430, Pergamon Press, New York, 1990Google Scholar
  203. Wilson WH, Jefferson JW. Thyroid disease, behavior, and psychopharmacology. Psychosomatics 26: 481–492, 1985PubMedCrossRefGoogle Scholar
  204. Wyszynski AA, Wyszynski B. Treatment of depression with fluoxetine in corticosteroid-dependent central nervous system Sjogren’s syndrome. Psychosomatics 34: 173–177, 1993PubMedCrossRefGoogle Scholar
  205. Yaryura-Tobias JA, Diamond B, Merlis S. Psychiatric manifestations of levodopa. Canadian Psychiatric Association Journal 17: SS123–SS128, 1972PubMedGoogle Scholar
  206. Young SN. Cholesterol, heart disease and the brain: an opportunity in research and a disaster in public health education? Journal of Psychiatry and Neuroscience 18: 1–3, 1993PubMedGoogle Scholar
  207. Yudofsky SC. β-Blockers and depression. The clinician’s dilemma. Journal of the American Medical Association 267: 1826–1827, 1992PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Scott B. Patten
    • 1
  • Edgar J. Love
    • 1
  1. 1.Department of Community Health Sciences, Faculty of MedicineThe University of CalgaryCalgaryCanada

Personalised recommendations